Found: 13
Select item for more details and to access through your institution.
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical‐stage soluble guanylate cyclase stimulator in rats.
- Published in:
- Pharmacology Research & Perspectives, 2020, v. 8, n. 2, p. 1, doi. 10.1002/prp2.579
- By:
- Publication type:
- Article
A Randomized, Placebo‐Controlled, Multiple‐Ascending‐Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 5, p. 564, doi. 10.1002/cpdd.627
- By:
- Publication type:
- Article
Two Cases of Complicated Intestinal Lipoma.
- Published in:
- American Journal of Gastroenterology (Springer Nature), 1979, v. 72, n. 1, p. 83
- By:
- Publication type:
- Article
PRO 2000 Gel Inhibits HIV and Herpes Simplex Virus Infection Following Vaginal Application: A Double - Blind Placebo - Controlled Trial.
- Published in:
- Journal of Infectious Diseases, 2006, v. 193, n. 1, p. 27, doi. 10.1086/498533
- By:
- Publication type:
- Article
The Topical Microbicide PRO 2000 Protects against Genital Herpes Infection in a Mouse Model.
- Published in:
- Journal of Infectious Diseases, 1999, v. 180, n. 1, p. 203, doi. 10.1086/314853
- By:
- Publication type:
- Article
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension.
- Published in:
- Diabetologia, 2020, v. 63, n. 4, p. 733, doi. 10.1007/s00125-019-05062-x
- By:
- Publication type:
- Article
Postcoital Bioavailability and Antiviral Activity of 0.5% PRO 2000 Gel: Implications for Future Microbicide Clinical Trials.
- Published in:
- PLoS ONE, 2010, v. 5, n. 1, p. 1, doi. 10.1371/journal.pone.0008781
- By:
- Publication type:
- Article
ACIDFORM Inactivates Herpes Simplex Virus and Prevents Genital Herpes in a Mouse Model: Optimal Candidate for Microbicide Combinations.
- Published in:
- Journal of Infectious Diseases, 2006, v. 194, n. 6, p. 795, doi. 10.1086/506948
- By:
- Publication type:
- Article
Crystallization, sequence, and preliminary crystallographic data for an antipeptide Fab 50.1 and peptide complexes with the principal neutralizing determinant of HIV-1 gpl20.
- Published in:
- Proteins, 1992, v. 14, n. 4, p. 499, doi. 10.1002/prot.340140410
- By:
- Publication type:
- Article
The Acceptability of an Investigational Vaginal Microbicide, PRO 2000 Gel, among Women in a Phase I Clinical Trial.
- Published in:
- Journal of Women's Health (15409996), 2003, v. 12, n. 7, p. 655, doi. 10.1089/154099903322404302
- By:
- Publication type:
- Article
Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
1073-P: Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Soluble Guanylate Cyclase Stimulator Praliciguat in Patients with Diabetic Kidney Disease.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1073-P
- By:
- Publication type:
- Article
Phase I safety study of 0.5% PRO 2000 vaginal Gel among HIV un-infected women in Pune, India.
- Published in:
- AIDS Research & Therapy, 2006, v. 3, p. 4, doi. 10.1186/1742-6405-3-4
- By:
- Publication type:
- Article